GLP-1 for People with Knee or Hip Problems

Introduction

The knee joint takes about 4 pounds of load for every 1 pound of body weight during normal walking. The hip carries about 3 pounds per pound. For a person 50 pounds above ideal weight, that means 200 extra pounds of force going through the knees with every step.

The link between obesity and joint disease is mechanical and inflammatory. Mechanical because higher load wears cartilage faster. Inflammatory because adipose tissue produces cytokines (IL-6, TNF-alpha, leptin) that drive joint inflammation independent of load. A 2017 Arthritis & Rheumatology paper estimated that obesity accounts for about 60% of attributable risk for knee osteoarthritis in U.S. adults.

The STEP 9 trial (Bliddal et al. 2024 NEJM) tested semaglutide specifically for knee osteoarthritis pain in adults with obesity. The results were striking. Pain on the WOMAC scale dropped 41.7 points on semaglutide versus 27.5 on placebo over 68 weeks. Physical function improved 41.5 points versus 26.7. The drug worked partly through weight loss and partly through other mechanisms.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Much Does Weight Affect Knee and Hip Pain?

Mechanically, a lot. Studies of gait biomechanics consistently show that knee joint reaction force scales 3 to 4 times body weight during normal walking and 5 to 6 times during stair climbing.

Quick Answer: Each pound of body weight produces 4 pounds of load on the knee during walking

The IDEA trial (Messier et al. 2013 JAMA) is the cleanest demonstration. 454 overweight and obese adults with knee osteoarthritis were randomized to diet, exercise, or both. The combined diet plus exercise group lost 10.6% body weight on average and reduced knee pain by 51% measured on the WOMAC scale. The diet-only group lost similar weight but had less pain reduction. The exercise-only group lost minimal weight and had modest pain reduction.

What this means: weight loss alone helps, exercise alone helps less, the combination is best. The 10% weight loss threshold is the most-studied target for knee osteoarthritis pain relief. Below 5% weight loss, effects are modest. Above 10%, effects are large.

Hip osteoarthritis has similar relationships to weight but slightly less strong evidence. The mechanical principle is the same. Most hip osteoarthritis trials show meaningful pain reduction with 5 to 10% weight loss.

What Did the STEP 9 Trial Actually Show?

STEP 9 enrolled 407 adults with obesity (BMI 30 or higher) and clinically significant knee osteoarthritis with moderate to severe pain. They were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. All participants received counseling for diet and physical activity.

Results: weight loss of 13.7% on semaglutide versus 3.2% on placebo. Pain reduction on the WOMAC scale of 41.7 points on semaglutide versus 27.5 on placebo (out of 100). Physical function improvement of 41.5 versus 26.7. The minimum clinically important difference for WOMAC pain is generally cited as 8 to 10 points, so both groups exceeded that, but semaglutide produced substantially larger benefit.

Importantly, the pain reduction was not fully explained by weight loss alone. Statistical modeling suggested that weight loss accounted for about 70 to 75% of the pain effect, with the remainder attributable to other mechanisms.

The trial also showed reduced use of pain medications (NSAIDs, acetaminophen, opioids) in the semaglutide group. Fewer patients escalated to injections or considered surgery during the trial period.

Why Does a GLP-1 Reduce Joint Pain Beyond Weight Loss?

Several proposed mechanisms. The most studied is reduction in inflammatory cytokines. Obesity drives chronically elevated IL-6, TNF-alpha, CRP, and leptin, all of which contribute to joint inflammation.

Weight loss reduces these markers, but GLP-1 medications appear to reduce them more than equivalent weight loss from other methods. A 2023 study in Cardiovascular Diabetology found that semaglutide reduced hs-CRP by about 40% over 68 weeks, with effects partly independent of weight loss.

GLP-1 receptors are expressed in synovial tissue, cartilage, and immune cells. There is direct biological effect on joint inflammation, not just systemic effect through weight reduction.

The clinical implication: people with severe knee osteoarthritis who have not been able to lose weight through other methods may benefit from GLP-1 therapy even before significant weight loss occurs. Pain improvement can begin in the first few months.

Should I Lose Weight Before Knee or Hip Replacement Surgery?

Strong evidence says yes. Multiple orthopedic studies show that obesity at the time of joint replacement surgery increases complications and reduces long-term implant survival.

A 2018 Journal of Arthroplasty meta-analysis found that BMI over 40 was associated with a 2.5-fold higher rate of deep infection and 1.8-fold higher rate of revision surgery after total knee replacement compared to normal-weight patients. BMI 35 to 40 also showed elevated risk.

Many orthopedic surgeons require BMI below 40 (sometimes 35) before scheduling elective joint replacement. The waiting period can be a frustrating chicken-and-egg situation: the joint pain limits exercise, which limits weight loss, which delays surgery.

GLP-1 therapy breaks this cycle. Weight loss without high-impact exercise is the strength of GLP-1s. Many patients reach surgical eligibility within 6 to 12 months.

The pre-surgical weight loss also produces secondary benefits: lower diabetes risk, lower blood pressure, lower anesthesia risk, faster recovery, and longer implant survival.

What About Recovery After Joint Replacement Surgery?

Surgical recovery on a GLP-1 has some specific considerations. The slowed gastric emptying interacts with anesthesia in ways that the ASA has addressed in recent guidance.

The 2023 American Society of Anesthesiologists guidance recommends considering longer fasting periods before procedures requiring sedation in patients on GLP-1 medications. Specific recommendations: hold the medication for 1 week before the procedure if it is a weekly injection (which covers semaglutide and tirzepatide), or extend fasting to 12 hours or more for emergency procedures.

The concern is aspiration risk from retained gastric contents under anesthesia. Several case reports have described this complication. The risk is small but real.

For elective joint replacement, plan the medication hold with both the prescribing clinician and the surgeon. Resume the medication after surgery once oral intake is restored, typically within 1 to 2 weeks.

Post-operative weight regain is a real risk. The combination of reduced mobility, increased pain, depression, and stopped medication can produce rapid weight regain. Resuming therapy promptly when safe helps prevent this.

Are There Specific Exercises I Can Do with Knee or Hip Pain on a GLP-1?

Yes. Low-impact options work well and combine with the appetite suppression and energy improvements from weight loss.

Swimming and aquatic therapy are standard recommendations for severe knee or hip osteoarthritis. Water reduces joint load to about 10 to 30% of body weight depending on depth. The American College of Rheumatology lists aquatic exercise as a strongly recommended intervention.

Cycling on a stationary bike or recumbent bike avoids the impact of running but builds leg strength. Resistance should be moderate, not high. Some patients with advanced osteoarthritis tolerate cycling better than walking.

Walking remains useful for most patients with mild to moderate joint pain. Walking on softer surfaces (treadmill, dirt path, grass) is gentler than concrete. The Arthritis Foundation Walk With Ease program is a structured 6-week walking program designed for patients with arthritis.

Resistance training, particularly for the muscles around the affected joint, is important. Quadriceps strengthening for knee osteoarthritis has the strongest evidence. Two sessions per week, with weights or bands, supplements weight loss and reduces lean mass loss from GLP-1 therapy.

Key Takeaway: The IDEA trial (Messier 2013 JAMA) showed 10% weight loss plus exercise cut knee pain 51%

What About Hyaluronic Acid, Cortisone Shots, and Other Injections?

GLP-1 therapy does not affect the efficacy of intra-articular injections. Many patients use both approaches concurrently.

Cortisone injections provide short-term pain relief for 4 to 12 weeks. The American Academy of Orthopaedic Surgeons gives them a moderate recommendation for knee OA. Repeated injections (more than 3 per year per joint) may accelerate cartilage loss.

Hyaluronic acid (viscosupplementation) has more controversial evidence. The 2019 AAOS guidelines do not recommend it for knee OA based on inconsistent evidence. Some patients report symptomatic improvement.

Platelet-rich plasma (PRP) injections have growing evidence for mild to moderate knee OA. Cost is high and insurance coverage is limited.

The strategic question is what is the long-term plan. For patients who plan eventual joint replacement, injections are bridging therapy. For patients who can preserve the joint with weight loss, exercise, and injections, the GLP-1 may delay or eliminate the need for surgery.

Can GLP-1s Help with Back Pain?

Indirectly. Most chronic back pain in adults with obesity has mechanical and inflammatory contributors that respond to weight loss.

A 2015 Spine Journal meta-analysis pooled studies of weight loss interventions and back pain. Pooled effect was about 30% pain reduction with 10% weight loss, similar in magnitude to medications and physical therapy.

Specific back conditions that respond well to weight loss: facet joint arthropathy, sacroiliac dysfunction, mechanical low back pain, sciatica from disc herniation in some cases. Conditions that respond less: severe central stenosis, multi-level fusion patients, severe scoliosis.

The mechanism is similar to knee and hip. Reduced mechanical load plus reduced systemic inflammation. The inflammatory piece may be particularly important for back pain given the role of cytokines in disc degeneration.

GLP-1 therapy has not been specifically tested for back pain. Real-world experience suggests benefit in many patients, particularly those with substantial weight loss.

What About Fibromyalgia and Chronic Widespread Pain?

Less direct evidence. Fibromyalgia is a central pain sensitization condition, not a mechanical or inflammatory joint disease. Weight loss alone has not been a reliable treatment.

A 2020 Pain Medicine review found modest benefit of weight loss for fibromyalgia in some studies but inconsistent results. The mechanism is unclear but may involve reduced peripheral inflammation, improved sleep, and improved mood.

GLP-1 therapy for fibromyalgia specifically has not been studied. Some patients report symptom improvement on GLP-1s, but this is anecdotal.

For patients with both fibromyalgia and obesity, GLP-1 therapy is appropriate for the obesity indication. Fibromyalgia treatment continues to follow standard protocols (duloxetine, pregabalin, exercise, CBT).

What Is the Long-term Plan for Joint Pain on a GLP-1?

Weight loss to or below the 5 to 10% threshold within 6 to 12 months, then maintenance. For some patients, this avoids surgery. For others, it makes eventual surgery safer and more durable.

Pain medication use typically drops as weight loss progresses. Many patients reduce NSAID use within 3 to 6 months. Opioid use, where it exists, can often be tapered. This conversation should be with the prescribing clinician, not handled solo.

Continued physical activity is essential. Weight loss without strengthening produces less pain improvement than weight loss with strengthening. The combination is more than additive.

For patients who eventually have joint replacement, the GLP-1 typically continues after recovery. Continued weight management protects the implant.

A TrimRx personalized treatment plan considers joint conditions when designing dose escalation and monitoring schedules.

Bottom line: Weight loss before joint replacement surgery reduces complications and may delay surgery

FAQ

How Long Until I Notice Joint Pain Improvement?

STEP 9 showed measurable pain reduction by week 12 and continued improvement through week 68. Most patients notice meaningful changes in 8 to 16 weeks, with continued benefit as weight loss progresses.

Can I Keep Taking My Arthritis Medications?

Yes. NSAIDs, acetaminophen, duloxetine, and other arthritis medications can continue. Many patients reduce or discontinue them over time as pain improves. Talk to the prescribing clinician about timing.

What If I Have Severe Arthritis and Cannot Exercise?

GLP-1 therapy works for weight loss without significant exercise, unlike most non-medication approaches. Pool exercise and chair-based resistance work are options when standing exercise is not.

Will Losing Weight Reverse My Arthritis?

Probably not reverse the cartilage damage that has occurred, but can significantly reduce pain and may slow progression. Patients with mild to moderate OA often achieve durable pain relief. Patients with severe OA may still benefit but eventually need surgery.

Should I Delay Knee Replacement to Try a GLP-1 First?

Worth discussing with your orthopedic surgeon. If you have BMI over 35 to 40 and surgery is being recommended, GLP-1 therapy for 6 to 12 months may make surgery safer and may improve pain enough that surgery is delayed.

Can I Exercise After a Cortisone Shot While on a GLP-1?

Yes. The medications do not interact. Most clinicians recommend reduced activity for 24 to 48 hours after injection, then resuming normal activity.

How Does This Work with Physical Therapy?

Synergistically. The weight loss reduces joint load, the medication may reduce inflammation directly, and physical therapy builds strength and motion. Combining all three produces better outcomes than any alone.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.